{"id":773,"date":"2015-11-01T12:02:00","date_gmt":"2015-11-01T11:02:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2015\/duale-hemmung-der-thrombozytenaggregation-nach-myokardinfarkt-auf-dauer"},"modified":"2022-03-17T14:13:16","modified_gmt":"2022-03-17T13:13:16","slug":"duale-hemmung-der-thrombozytenaggregation-nach-myokardinfarkt-auf-dauer","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2015\/duale-hemmung-der-thrombozytenaggregation-nach-myokardinfarkt-auf-dauer","title":{"rendered":"Duale Hemmung der Thrombozytenaggregation nach Myokardinfarkt \u2013 auf Dauer?"},"content":{"rendered":"<p>Ticagrelor ist ein oraler Thrombozytenaggregationshemmer, der nur in Kombination mit Azetylsalizyls\u00e4ure (ASS) zugelassen ist (sog. DAT = duale Hemmung der Thrombozytenaggregation). Die Zulassung umfasst die Behandlung von Patienten mit akuten Koronarsyndromen (ACS), d.h. instabile Angina pectoris (iAP), Myokardinfarkt mit (STEMI) oder ohne ST-Strecken-Hebung (NSTEMI), unabh\u00e4ngig davon, ob die Patienten konservativ, mittels perkutaner Koronarintervention (PCI) oder [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ticagrelor ist ein oraler Thrombozytenaggregationshemmer, der nur in Kombination mit Azetylsalizyls\u00e4ure (ASS) zugelassen ist (sog. DAT = duale Hemmung der Thrombozytenaggregation). Die Zulassung umfasst die Behandlung von Patienten mit akuten Koronarsyndromen (ACS), d.h. instabile Angina pectoris (iAP), Myokardinfarkt mit (STEMI) oder ohne ST-Strecken-Hebung (NSTEMI), unabh\u00e4ngig davon, ob die Patienten konservativ, mittels perkutaner Koronarintervention (PCI) oder [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[74,684,495,137,1272,77,76,71,498,65,2006,1033,727,2005],"class_list":["post-773","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-acetylsalicylsaeure","tag-akutes-koronarsyndrom","tag-angina-pectoris","tag-antikoagulanzien","tag-arteriosklerose","tag-ass","tag-azetylsalizylsaeure","tag-herzinfarkt","tag-koronare-herzkrankheit","tag-myokardinfarkt","tag-pegasus-timi-54-studie","tag-prasugrel","tag-thrombozytenaggregationshemmer","tag-ticagrelor"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/773","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=773"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/773\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=773"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=773"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=773"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}